Ardena Expands Bioanalytical Services in Europe

01-Nov-2024 - Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with GMP facilities in Belgium, Spain, the Netherlands and Sweden, announced a substantial expansion of its Bioanalytical Services in the Netherlands. This strategic investment includes establishing a ...

Revealing DNA behavior in record time

26-Aug-2024 - “DNA, RNA and proteins are the key players to regulate all processes in the cells of our body,” Leiden Professor John van Noort explains. “To understand the (mis-)functioning of these molecules, it is essential to uncover how their 3D structure depends on their sequence and for this it is ...

UMC Utrecht and VectorY Therapeutics collaborate in ALS Biomarker Study

Finding these biomarkers is expected to help diagnose ALS and monitor disease progression and improve the design of future clinical studie

18-Jun-2024 - UMC Utrecht has enrolled its first patient for a new study to identify biomarkers of Amyotrophic Lateral Sclerosis (ALS). The observational investigator-initiated study is led by Professor Dr. Leonard van den Berg and supported by VectorY Therapeutics. VectorY Therapeutics is developing ...

Portable AI-based test kit to identify bacterial infections

Dutch scientist selected as a finalist for the Young Inventors Prize 2024: Her startup focuses on the most common types of infection

11-Jun-2024 - According to a study published in The Lancet, one in eight global deaths in 2019 was caused by common bacterial infections, which are the second leading cause of death worldwide. Due to slow or ineffective diagnostics many treatments are carried out with limited information on the condition, ...

Cloud-based platform for analyzing cryo-EM data secures pre-seed investment

Dutch biotech start-up aims to accelerate the development of new active ingredients

04-Mar-2024 - CryoCloud, a biotech start-up based in Utrecht in the Netherlands, recently closed a financing round of 500,000 euros. The company has thus reached an important milestone on its way to optimizing cryo-electron microscopy (cryo-EM). CryoCloud was founded in 2021 by Munich-based Robert Englmeier, ...

Autonomous synthesis robot uses AI to speed up chemical discovery

Impressive ingenuity

30-Jan-2024 - Chemists of the University of Amsterdam (UvA) have developed an autonomous chemical synthesis robot with an integrated AI-driven machine learning unit. Dubbed ‘RoboChem’, the benchtop device can outperform a human chemist in terms of speed and accuracy while also displaying a high level of ...

Researchers discover new ultra strong material for microchip sensors

A material that doesn't just rival the strength of diamonds and graphene, but boasts a yield strength 10 times greater than Kevlar

06-Nov-2023 - Researchers at Delft University of Technology, led by assistant professor Richard Norte, have unveiled a remarkable new material with potential to impact the world of material science: amorphous silicon carbide (a-SiC). Beyond its exceptional strength, this material demonstrates mechanical ...

QIAGEN expands Supervisory Board with appointment of a new member

23-Feb-2021 - QIAGEN announced the appointment of Thomas Ebeling, a leading international executive with extensive experience in the healthcare, media and consumer goods industries, as a member of the Supervisory Board with immediate effect. Mr. Ebeling joins QIAGEN as part of a process launched by the ...

Thermo Fisher Scientific and QIAGEN N.V. Agree on Amended Terms to Acquisition Agreement

Offer price increased

17-Jul-2020 - Thermo Fisher Scientific Inc. and QIAGEN N.V. announced that they have entered into an amendment to their acquisition agreement under which Thermo Fisher has commenced a tender offer to acquire all of the ordinary shares of QIAGEN. The amendment provides for an increase from the original offer ...

Thermo Fisher Scientific to Acquire QIAGEN

03-Mar-2020 - Thermo Fisher Scientific Inc. and QIAGEN N.V. announced that their boards of directors, as well as the managing board of QIAGEN N.V., have unanimously approved Thermo Fisher’s proposal to acquire QIAGEN for €39 per share in cash. The offer price represents a premium of approximately 23% to the ...